Selegiline in Parkinson's disease.
作者信息
Calne D B
出版信息
BMJ. 1995 Dec 16;311(7020):1583-4. doi: 10.1136/bmj.311.7020.1583.
Abstract
摘要
相似文献
1
Selegiline in Parkinson's disease.司来吉兰治疗帕金森病
BMJ. 1995 Dec 16;311(7020):1583-4. doi: 10.1136/bmj.311.7020.1583.
2
Mortality associated with selegiline in Parkinson's disease. What do the available data mean?帕金森病中与司来吉兰相关的死亡率。现有数据意味着什么？
Drug Saf. 1997 May;16(5):289-94. doi: 10.2165/00002018-199716050-00001.
3
Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.左旋多巴与左旋多巴联合司来吉兰治疗早期轻度帕金森病患者的疗效及死亡率数据比较。英国帕金森病研究小组。
BMJ. 1995 Dec 16;311(7020):1602-7. doi: 10.1136/bmj.311.7020.1602.
4
Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.司来吉兰对帕金森病患者死亡率的影响：一项荟萃分析。
Neurology. 1998 Sep;51(3):825-30. doi: 10.1212/wnl.51.3.825.
5
[Drug therapy of Parkinson's disease].[帕金森病的药物治疗]
Duodecim. 1997;113(18):1827-34.
6
Future therapies for Parkinson's disease.帕金森病的未来疗法。
Neurol Clin. 2004 Oct;22(3 Suppl):S149-66. doi: 10.1016/j.ncl.2004.05.005.
7
Selegiline: a second look. Six years later: too risky in Parkinson's disease.司来吉兰：再审视。六年后：对帕金森病风险过高。
Prescrire Int. 2002 Aug;11(60):108-11.
8
Transdermal selegiline (Emsam).
Med Lett Drugs Ther. 2006 May 22;48(1235):41-2.
9
Monoamine oxidase inhibitors--is it time to up the TEMPO?单胺氧化酶抑制剂——是时候加快节奏了吗？
Lancet Neurol. 2003 Mar;2(3):142-3. doi: 10.1016/s1474-4422(03)00318-1.
10
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.第二代单胺氧化酶抑制剂雷沙吉兰治疗帕金森病的综合综述。
Clin Ther. 2007 Sep;29(9):1825-49. doi: 10.1016/j.clinthera.2007.09.021.
引用本文的文献
1
Monoamine oxidase B inhibitors for early Parkinson's disease.用于早期帕金森病的单胺氧化酶B抑制剂
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD004898. doi: 10.1002/14651858.CD004898.pub2.
2
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Parkinson's disease is rarely a primary cause of death.在早期轻度帕金森病中左旋多巴添加司来吉兰的效果。帕金森病很少是主要死因。
BMJ. 1996 Mar 16;312(7032):703; author reply 704-5. doi: 10.1136/bmj.312.7032.703.
3
Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Stopping selegeline may lead to problems for patients.在早期轻度帕金森病中左旋多巴加用司来吉兰的效果。停用司来吉兰可能给患者带来问题。
BMJ. 1996 Mar 16;312(7032):702; author reply 704-5. doi: 10.1136/bmj.312.7032.702.
本文引用的文献
1
Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study.司来吉兰能否延缓帕金森病的进展？对DATATOP研究的批判性重新评估。
J Neurol Neurosurg Psychiatry. 1994 Feb;57(2):217-20. doi: 10.1136/jnnp.57.2.217.
2
Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.司来吉兰联合左旋多巴-卡比多巴与单用左旋多巴-卡比多巴治疗帕金森病的对比研究。
Ann Neurol. 1995 Jan;37(1):95-8. doi: 10.1002/ana.410370117.
3
Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study.
J Neural Transm. 1985;64(2):113-27. doi: 10.1007/BF01245973.
4
Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients.司来吉兰作为帕金森病传统左旋多巴治疗的辅助药物。200例患者使用这种B型单胺氧化酶抑制剂的经验。
Arch Neurol. 1989 Dec;46(12):1280-3. doi: 10.1001/archneur.1989.00520480022013.
5
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
Science. 1989 Aug 4;245(4917):519-22. doi: 10.1126/science.2502843.
6
Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMT).司来吉兰用于初发帕金森病患者：法国司来吉兰多中心试验（FSMT）。
Acta Neurol Scand Suppl. 1991;136:73-8. doi: 10.1111/j.1600-0404.1991.tb05024.x.
7
Selegiline as initial treatment in de novo parkinsonian patients.司来吉兰作为初发帕金森病患者的初始治疗药物。
Neurology. 1992 Feb;42(2):339-43. doi: 10.1212/wnl.42.2.339.
8
The oxidant stress hypothesis in Parkinson's disease: evidence supporting it.
Ann Neurol. 1992 Dec;32(6):804-12. doi: 10.1002/ana.410320616.
9
The free radical hypothesis in idiopathic parkinsonism: evidence against it.
Ann Neurol. 1992 Dec;32(6):799-803. doi: 10.1002/ana.410320615.
10
The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic.司来吉兰的抗帕金森病疗效源于可能是对症的短暂改善。
Ann Neurol. 1992 Dec;32(6):795-8. doi: 10.1002/ana.410320614.
Zotero 插件